Serena Williams and GLP‑1 Medications: How the Tennis Champion’s Health Shift Is Reshaping Public Conversation on Weight, Performance and Longevity

Table of Contents

1. Key Highlights:
2. Introduction
3. From champion athlete to patient: why her disclosure matters
4. What GLP‑1 medications do—and why they matter to metabolic health
5. How medication and movement intersect: Williams’ shift to running and Pilates
6. Celebrity endorsement, marketing and the Ro Super Bowl ad
7. Stigma, public reaction and the politics of choice
8. Safety, tolerability and the need for medical supervision
9. Supply, access and the economics of long‑term therapy
10. Athletic regulations, testing and the rumor mill
11. What Serena’s language—“longevity,” “lifetime thing”—means in clinical terms
12. Real‑world examples: how patient experiences align with trial data
13. Practical guidance for readers considering GLP‑1 therapy
14. The research horizon: what scientists are watching next
15. Cultural effects: beyond biology to norms and expectations
16. The role of telehealth and direct‑to‑consumer delivery
17. Where the conversation goes from here
18. FAQ

Key Highlights:

• Serena Williams reports a 34-pound weight loss and a roughly 30% drop in cholesterol after about 18 months on a GLP‑1 medication; she credits the change with higher energy, improved metabolic markers and a renewed enjoyment of exercise.
• Williams will appear in a Super Bowl ad for telehealth company Ro and says she plans to remain on GLP‑1 treatment long term, framing it as part of her health story despite public stigma and debate.
• Her experience crystallizes tensions between celebrity influence, access and affordability, clinical guidance and the evolving science of GLP‑1 therapies for weight and metabolic health.

Introduction

Serena Williams, one of the most recognized athletes of her generation, framed a new chapter in her public life this month: an embrace of a medication that has become central to national conversations about weight, health and medical care. Visiting studio 1A to announce a Super Bowl commercial for Ro, Williams spoke candidly about what she calls a transformed relationship with her body since starting a GLP‑1 medication about a year and a half ago. The changes she described are not only physical; she emphasized greater energy, improved bloodwork and a mental lightness that has altered how she trains, parents and plans for the future.

Her disclosure arrived at a moment when GLP‑1 receptor agonists and related drugs are reshaping clinical practice and consumer demand. Developed initially to treat type 2 diabetes, these medications now play a leading role in approved weight‑management therapies and off‑label use. For public figures like Williams, the decision to disclose and to appear in a national marketing campaign intersects with complex medical, ethical and cultural questions: Which patients benefit most? How should clinicians weigh long‑term safety against real short‑term gains? What happens when a private health choice becomes a public message with powerful reach?

This article examines what Williams revealed, situates her experience within what clinicians and trials say about GLP‑1 drugs, explores how celebrity narratives shift public behavior and policy, and outlines practical considerations for people thinking about these medications for weight or metabolic health.

From champion athlete to patient: why her disclosure matters

Williams’ account carries unusual weight because she was not speaking from the perspective of a sedentary patient trying a new treatment. She described blood tests from her playing days that showed elevated cholesterol and markers placing her at risk for heart disease despite being at the height of her professional career. “Some of these numbers are from when I was literally winning Grand Slams,” she said. “I was dominating. I was at risk for heart disease, and I didn’t even know. … That’s scary.”

The revelation reframes a familiar public assumption: that elite athleticism guarantees perfect cardiometabolic health. It also signals a broader truth clinicians encounter often—the presence of unfavorable metabolic markers in people who outwardly appear fit. That dissonance has medical implications. Elevated LDL cholesterol, for example, contributes to atherosclerosis irrespective of activity level; addressing it can reduce long‑term cardiovascular risk.

Her decision to begin a GLP‑1 medication after the birth of her second daughter also underscores how life transitions—parenthood, aging, recovery from pregnancy—can change metabolic needs and medical priorities. Williams described multiple attempts at weight control before the medication: “I was doing everything,” she said. After starting GLP‑1 therapy, she reports losing 34 pounds and seeing “my blood sugar is better” and cholesterol fall by roughly 30%.

Those outcomes echo what many clinicians see in practice: for selected patients under medical supervision, GLP‑1 medications can substantially reduce weight and improve metabolic measures. The difference here is scale and spotlight. When a global sports icon talks about measurable health changes and a commitment to long‑term medication use, the messaging moves from clinical literature into everyday conversation. That shift affects how people perceive the treatments, how demand flows to clinics and pharmacies, and how insurers and regulators respond.

What GLP‑1 medications do—and why they matter to metabolic health

GLP‑1 stands for glucagon‑like peptide‑1, a hormone that influences appetite, digestion and blood sugar regulation. Pharmaceutical GLP‑1 receptor agonists mimic this hormone’s action: they slow gastric emptying, increase feelings of fullness, reduce appetite and enhance insulin secretion when glucose levels are high. This combination helps lower blood glucose and can lead to substantial weight loss when paired with lifestyle changes and medical oversight.

Clinical trials for modern GLP‑1 agents have produced pronounced weight‑loss results compared with older therapies. Newer compounds, used at higher doses for weight management, have moved the needle from single‑digit percentages of body weight to consistent double‑digit reductions in many participants. Those metabolic gains—improved glycemic control, reductions in certain lipid measures and declines in blood pressure for some—translate into plausible benefits for cardiovascular risk, which is why clinicians treating diabetes and obesity now prioritize these drugs in many cases.

GLP‑1 therapies fall into two broad clinical categories: those developed and approved primarily for type 2 diabetes, and higher‑dose preparations authorized specifically for weight management. Both categories share mechanisms of action, but dosing, monitoring and regulatory frameworks differ. Some related drugs combine GLP‑1 activity with other hormonal pathways to amplify weight loss; the science is active and evolving.

Safety and tolerability are central to clinical decision‑making. Common side effects include gastrointestinal symptoms—nausea, vomiting, diarrhea and constipation—which tend to diminish over time. Rare but serious concerns remain under investigation, including potential links to pancreatitis and gallbladder disease. For people with a history of certain endocrine tumors, GLP‑1s might carry specific risks and are generally avoided. Long‑term safety data beyond the span of several years remain limited, so physicians counsel ongoing monitoring and individualized decisions about continuing therapy.

When Williams says GLP‑1 therapy is “a lifetime thing,” she’s articulating a frequent clinical reality: substantial weight regain commonly occurs after stopping these medications. That pattern leads some patients and doctors to view GLP‑1s as chronic treatments to manage a chronic condition—weight and metabolic dysregulation—similar to how diabetes or hypertension is treated over years. That framing carries financial, emotional and logistic consequences for patients and health systems.

How medication and movement intersect: Williams’ shift to running and Pilates

The story Williams tells is not one of medication alone but of medication enabling renewed physical activity. She credits GLP‑1 treatment with higher energy, a sense of lightness and newfound consistency in exercise habits. “I started doing more Pilates … I love running, and I never thought I would keep running, but I love it now,” she said, describing a return to both reformer Pilates and running she hadn’t anticipated sustaining.

Reformer Pilates is a demanding, full‑body conditioning method that emphasizes core strength, flexibility and control. For people who spend years focusing on sport‑specific training, such cross‑training can relieve overused structures, build complementary strength and reduce injury risk. Running, meanwhile, is an accessible form of aerobic conditioning that benefits cardiovascular fitness, mood and bone health when implemented sensibly.

Williams’ account illustrates a therapeutic principle: when a medical intervention reduces physiological barriers—persistent hunger, low energy, or metabolic dysregulation—behavioral habits can shift. Appetite suppression and improved glycemic control may make it easier for patients to engage consistently in exercise, and the positive feedback loop of movement enhancing mood and sleep further supports adherence.

That dynamic also highlights the difference between weight loss and health optimization. She said: “It's more about … not even the weight loss, but it’s about longevity.” Reducing cardiometabolic risk factors, increasing physical activity and improving mental well‑being are distinct but overlapping outcomes. For many patients, the medication is a tool that facilitates sustainable lifestyle changes rather than a standalone cure.

Celebrity endorsement, marketing and the Ro Super Bowl ad

Williams’ appearance in Ro’s first Super Bowl commercial brings healthcare marketing to a mass audience that rarely sees nuanced medical messaging in such a high‑visibility slot. Ro is a telehealth company that offers direct‑to‑consumer diagnosis and treatment for conditions ranging from sexual health to weight management; the company’s model leans on convenience, online consultations and prescription delivery.

Celebrity partnerships amplify brand recognition and accelerate consumer interest. They also invite scrutiny. Williams disclosed that her husband, Alexis Ohanian, is an investor in Ro—a detail that adds transparency but also raises understandable questions about conflicts of interest and the commercial dimensions of medical endorsements.

The ad campaign will likely generate new patient inquiries and sign‑ups, a pattern observed whenever celebrities associate with health products. That influx can strain clinical services when demand exceeds supply, and it can prompt regulatory attention when promotional claims outpace the nuanced realities of clinical care. The key difference between entertainment and medicine is accountability: healthcare decisions require individualized assessment, monitoring and follow‑up that a 30‑second ad cannot convey.

Williams’ decision to speak publicly while also participating in Ro’s advertising highlights a tension felt across healthcare today: commercial channels extend access and awareness but can also bypass checks that guard patient safety—appropriate screening for contraindications, baseline labs and long‑term follow‑up. The challenge falls to clinicians, regulators and companies to ensure that increased accessibility does not come at the cost of quality care.

Stigma, public reaction and the politics of choice

Public reactions to celebrity disclosures about weight and medications split between empathy and judgment. Williams acknowledged facing stigma about using GLP‑1s but also receiving encouragement. That mixed response reflects cultural attitudes toward body size, responsibility for health and the perceived fairness of access to novel therapies.

Stigma operates at multiple levels. Some critics frame GLP‑1 use as a shortcut that undermines discipline; others worry about the medicalization of normal body variation or the prioritization of aesthetics over systemic health inequities. At the same time, many patients describe the real, measurable health benefits that enable them to participate more fully in life—work, parenting and daily activities.

Policy debates add another layer. If GLP‑1s are medically appropriate for people with obesity or metabolic disease, equitable access becomes a public health question. But the current market dynamics—direct‑to‑consumer telehealth, high out‑of‑pocket costs and episodic shortages—create disparities. Celebrity exposure can rapidly compound demand, which intensifies affordability and supply concerns and may exacerbate existing inequalities.

The politics of choice also intersect with clinical ethics. Patients and clinicians must balance respect for autonomy—the right to decide what treatments to pursue—with beneficence and nonmaleficence, the obligations to help and to avoid harm. When a medication shows clear benefits for an individual, stigmatizing their choice risks undermining trust in medical care.

Safety, tolerability and the need for medical supervision

Serena Williams’ positive experience does not negate the need for careful medical oversight. GLP‑1 medications are powerful agents with clear physiological effects and potential adverse events that require monitoring. Common side effects are primarily gastrointestinal—nausea, early satiety, vomiting and constipation—and they often improve with time and dose adjustment. Clinicians typically initiate therapy at low doses and titrate upward to reduce intolerance.

Less common but clinically meaningful issues include gallbladder disease and pancreatitis signals in some patient populations. There are theoretical concerns about thyroid C‑cell tumors linked to animal studies, leading regulators to counsel caution in patients with a personal or family history of certain thyroid cancers. Clinicians also consider interactions with other medications and preexisting conditions before initiating therapy.

Long‑term outcomes remain an essential area of inquiry. The pharmacologic suppression of appetite and sustained weight reduction are beneficial for many cardiometabolic endpoints, but understanding how chronic exposure influences physiology over decades—especially when started at younger ages—requires ongoing surveillance and registries. That uncertainty is why many physicians recommend clear treatment goals, regular follow‑up labs and a shared decision‑making approach that outlines potential benefits and risks.

For athletes or individuals undergoing anti‑doping testing, the regulatory landscape complicates decisions. Current anti‑doping codes evaluate substances based on performance enhancement potential and health risk, but many GLP‑1 agents are not prohibited. Athletes contemplating these drugs should coordinate with team physicians and testing authorities to ensure compliance with sports’ rules and to document medical necessity.

Supply, access and the economics of long‑term therapy

One immediate consequence of celebrity disclosures and rising public interest has been surging demand. When a class of medication dramatically improves outcomes for a condition that affects millions, supply constraints and pricing pressures follow. Manufacturing capacity, raw material availability and distribution networks all shape how easily patients can obtain prescriptions.

Insurance coverage varies. For people with clinically recognized obesity or related comorbidities, some plans have begun covering weight‑management GLP‑1 treatments, but many insurers classify them differently for weight loss versus diabetes treatment, affecting prior authorization and out‑of‑pocket costs. When medications are used off‑label, coverage becomes more restrictive.

Cost‑effectiveness calculations complicate policy choices. If long‑term GLP‑1 therapy reduces cardiovascular events and diabetes complications, payers may find coverage economically justified. Yet those long‑term savings are projections dependent on continued adherence and real‑world effectiveness. In the short term, high price tags and chronic use raise equity concerns: patients with means can access sustained therapy, while those without financial resources may be left behind.

Telehealth models, like Ro’s, attempt to reduce barriers by offering virtual consultations and prescription fulfillment, but that convenience does not eliminate the need for baseline assessments—labs, medication reconciliation and follow‑up. Sustainable policy will require aligning coverage, manufacturing scale‑up and clinical infrastructure for monitoring to ensure equitable, high‑quality care.

Athletic regulations, testing and the rumor mill

Williams’ brief registration last fall with the International Tennis Integrity Agency’s (ITIA) drug‑testing system fed speculation that she might resume a professional career. She subsequently reported she was not returning to competition. The registration, however, underscores a practical detail for athletes: registering with testing agencies or ensuring transparent medical documentation is a routine part of returning to elite sport after using prescription medications.

Most GLP‑1 medications do not fall under prohibited substance lists maintained by major anti‑doping agencies, but rules evolve and vary across sports and levels. A safe path for competitive athletes involves early consultation with sports medicine specialists, obtaining therapeutic use exemptions where applicable, and maintaining meticulous records. The stakes include potential sanctions if rules are misunderstood or if testing reveals unexpected substances.

For retired professional athletes who train and compete recreationally, anti‑doping constraints are less likely to constrain personal medical decisions. Still, the visibility of an athlete like Williams navigating these choices draws attention to how sports bodies, clinicians and athletes coordinate around medications that alter physiology in ways that could affect performance.

What Serena’s language—“longevity,” “lifetime thing”—means in clinical terms

When Williams emphasizes “longevity” and calls GLP‑1s “a lifetime thing,” she taps into a growing clinical conception: obesity and related metabolic dysfunction are chronic states that may require long‑term management. The implication is practical and philosophical. Practically, many patients experience significant weight regain upon stopping GLP‑1 therapy, prompting clinicians to discuss indefinite maintenance strategies. Philosophically, the label “chronic condition” reframes obesity from a moral failing to a biomedical problem often responsive to sustained intervention.

That framing aligns with contemporary approaches to other chronic diseases. Hypertension, type 2 diabetes and hyperlipidemia are commonly managed with lifelong medications combined with lifestyle modifications. If obesity is treated in the same paradigm, it invites a recalibration of care delivery and insurance models: long‑term access, monitoring systems, multidisciplinary care teams and public health strategies to address upstream drivers of weight gain.

Williams’ emphasis on longevity also shifts the conversation beyond aesthetics. Her reported 30% cholesterol reduction and improved blood sugar underscore the potential for metabolic risk reduction—outcomes with clear implications for cardiovascular disease prevention. The clinical objective, when appropriate, is to lower the incidence of heart attacks, strokes and diabetes complications, not to pursue arbitrary weight targets.

Real‑world examples: how patient experiences align with trial data

Clinical trials provide controlled estimates of efficacy; real‑world use fills in gaps around tolerability, adherence and diverse patient populations. Patients who begin GLP‑1 therapies often report the same constellation Williams described: reduced hunger, less preoccupation with food, improved markers on laboratory testing and greater capacity for physical activity. These effects, combined with supportive behavioral interventions, enhance sustained benefits for many.

Yet variability matters. Not all patients respond the same way. Some achieve substantial weight loss and durable metabolic improvements; others encounter limiting side effects or only modest change. Socioeconomic status, comorbidities, psychological factors and access to multidisciplinary support all shape outcomes.

Consider two hypothetical patient profiles that illustrate divergent trajectories:

• A middle‑aged patient with obesity and prediabetes starts a GLP‑1 under close medical supervision, receives nutritional counseling and gradually increases physical activity. Over 12 months, they lose significant weight, reverse prediabetes and maintain improved labs while experiencing manageable nausea during dose escalation. Long‑term follow‑up focuses on metabolic monitoring and behavioral support.
• A younger patient without metabolic disease seeks GLP‑1 therapy primarily for cosmetic weight concerns and obtains medication via a telehealth visit without comprehensive baseline testing or follow‑up. They experience intolerable gastrointestinal symptoms and discontinue after brief use. No long‑term monitoring occurs, and transient supply shortages limit future access.

Those contrasting outcomes demonstrate why individualization, appropriate indications and medical oversight matter.

Practical guidance for readers considering GLP‑1 therapy

Serena Williams’ experience will prompt many readers to ask whether GLP‑1 therapy is right for them. Practical, medically sound steps include:

• Start with an evaluation. A clinician should review medical history, current medications, baseline labs (including glucose and lipid panels) and contraindications before prescribing.
• Establish clear goals. Define what success looks like: weight loss, improved glycemic control, reduced cardiovascular risk, or improved functional capacity.
• Expect a titration period. Most regimens begin at low doses and progress slowly to reduce side effects.
• Plan for monitoring. Regular follow‑up appointments and periodic labs are essential to track benefits and detect potential adverse events.
• Discuss duration. Talk candidly about whether the treatment is temporary or intended as long‑term maintenance and the implications of stopping.
• Consider lifestyle support. Medication combined with nutrition counseling, physical activity and behavioral support yields better and more durable outcomes.
• Understand costs and coverage. Check insurance coverage and explore patient assistance programs; be mindful of potential supply fluctuations.
• Prioritize safety for athletes. Competitive athletes should consult sports medicine and anti‑doping authorities as needed.
• Beware of one‑size‑fits‑all solutions. What works for a high‑profile figure may not translate directly; medical decisions require individual assessment.

These steps prioritize safety and align expectations with clinical realities.

The research horizon: what scientists are watching next

Researchers are tracking several pressing questions. Among them:

• Long‑term safety: Extended surveillance will clarify rare but important risks and how chronic pharmacologic appetite suppression affects physiology over decades.
• Durability of benefit: Studies are exploring strategies—combination therapies, staggered dosing and lifestyle intensification—to sustain weight loss after medication initiation and to reduce the need for indefinite therapy.
• Combination and next‑generation agents: Drugs that combine GLP‑1 activity with other hormonal targets have delivered larger weight losses in trials, and their comparative benefits, risks and costs will shape future treatment paradigms.
• Population health impact: If broader use reduces cardiovascular events at the population level, policymakers will grapple with coverage decisions, prioritization and resource allocation.
• Equity and access: Real‑world research will track who benefits and who gets left behind, guiding interventions to reduce disparities.

These research threads will determine whether the initial enthusiasm around GLP‑1s matures into sustained, equitable public health gains.

Cultural effects: beyond biology to norms and expectations

When a global icon speaks about a medical intervention, social norms shift. Williams’ candor could reduce stigma for some patients, provide validation for others who have struggled, and accelerate demand for clinical services. It might also intensify pressure on certain populations to pursue medicalized weight loss as a normative practice.

Public health messaging needs to preserve nuance: recognizing the medical legitimacy of GLP‑1 therapy for many patients while resisting reductive narratives that equate success solely with weight loss. Clinicians and communicators have a responsibility to contextualize celebrity experiences within evidence‑based recommendations and to emphasize comprehensive care.

The role of telehealth and direct‑to‑consumer delivery

Ro’s model—online consultation, virtual follow‑up and medication shipment—has democratized access to medical care in some respects. It offers convenience for many patients managing busy lives, including parents like Williams. Yet convenience does not replace comprehensive care. Baseline testing, medication reconciliation, and periodic in‑person evaluations remain important for a subset of patients.

Telehealth can be an integral part of a continuum of care when it coordinates with primary care, specialists and local labs. Companies and regulators will need to ensure that telehealth platforms maintain rigorous clinical protocols, follow‑up standards and transparent disclosure of conflicts of interest in advertising and endorsements.

Where the conversation goes from here

Serena Williams’ public health narrative is consequential. It demonstrates how modern medicine, consumer culture and celebrity influence intersect in ways that can hasten the diffusion of therapies—both appropriately and problematically. Her story underscores that metabolic health is multidimensional: labs, physical performance, mental well‑being and daily functioning interact.

For clinicians, the imperative is clear: provide individualized counsel, monitor outcomes, and engage patients in shared decision‑making. For health systems and policymakers, the work involves ensuring equitable access, scaling manufacturing and coverage responsibly, and investing in long‑term safety monitoring. For the public, Williams’ experience is a reminder that medical choices deserve thoughtful deliberation beyond the headlines.

FAQ

Q: What exactly is a GLP‑1 medication? A: GLP‑1 receptor agonists are drugs that mimic the action of the hormone glucagon‑like peptide‑1. They reduce appetite, slow gastric emptying and enhance insulin response to high blood glucose. They were developed for diabetes treatment and have broader applications in weight management at higher doses.

Q: Did Serena Williams lose weight because of GLP‑1s alone? A: Williams describes a combination of medication and increased physical activity—running and reformer Pilates—and improved energy and mood. Clinically, medication often facilitates adherence to lifestyle changes but is most effective as part of a comprehensive plan.

Q: Are GLP‑1 drugs safe for long‑term use? A: Long‑term data beyond several years are still emerging. Short‑ and medium‑term data show substantial benefits for many patients, with common side effects being gastrointestinal. Rare but serious risks are under continued study. Medical supervision and periodic monitoring are essential.

Q: Can competitive athletes use GLP‑1 medications? A: Many GLP‑1 medications are not on anti‑doping prohibited lists, but rules differ across sports and organizations. Competitive athletes should consult team physicians and anti‑doping authorities to navigate regulations and document medical necessity.

Q: Why is Serena’s involvement with Ro controversial to some people? A: Celebrities amplify public interest and can boost demand rapidly. When a celebrity also has a personal or familial financial connection to a company—Ohanian’s investment in Ro in this case—questions about conflicts of interest arise. Transparency helps, but the underlying tension between commercial marketing and medical oversight persists.

Q: Will more people now seek GLP‑1 treatment because of Serena’s story? A: Public figures influence health behavior. Increased interest is likely, but medical appropriateness varies. Clinicians should evaluate individual risks, benefits and monitoring needs before prescribing.

Q: How much do these medications cost and is insurance likely to cover them? A: Costs vary by drug, dose and insurance policy. Some insurers cover GLP‑1 therapies for diabetes and increasingly for obesity when certain clinical criteria are met, while others limit coverage. Patients should check plan details and ask providers about assistance programs.

Q: What should someone considering GLP‑1 therapy do first? A: Schedule a medical evaluation with a clinician to review medical history, baseline labs and treatment goals. Discuss potential side effects, dosing schedules, monitoring plans and whether the medication is likely to address the individual's health priorities.

Q: If a person stops the medication, will the weight return? A: Weight regain after stopping is common for many patients. Strategies to mitigate regain include behavioral support, continued lifestyle interventions and maintenance approaches guided by a clinician. Decisions about duration of therapy should be individualized.

Q: How can healthcare systems ensure equitable access if demand keeps rising? A: Systems must expand coverage policies based on clinical evidence, scale manufacturing sustainably, invest in clinician training and create multidisciplinary pathways that combine medication with behavioral and social supports. Policy choices should prioritize high‑need populations to reduce disparities.

Q: What questions remain unanswered about GLP‑1 therapies? A: Key questions concern long‑term safety, the optimal duration of therapy for various patient groups, comparative effectiveness across new drug combinations, and strategies to maintain benefits while minimizing costs and side effects. Ongoing trials and real‑world registries will address many of these unknowns.

Q: Does taking a GLP‑1 medication mean someone failed at diet and exercise? A: No. Chronic weight regulation involves complex biological systems. For many patients, GLP‑1 therapy complements diet and exercise by altering physiological drivers of hunger and satiety. Labeling medical treatment as failure ignores both the biology and the clinical benefits it can bring.

Q: Where can patients find reliable information? A: Patients should consult licensed clinicians, professional society guidelines and peer‑reviewed medical literature. Trusted health systems and specialty clinics can provide comprehensive evaluations and follow‑up plans. When using telehealth services, verify the provider’s credentials and the company’s clinical protocols.

Serena Williams’ public discussion of GLP‑1 medication and her new role in a national ad campaign bring medical science into everyday conversation in a powerful way. Her experience highlights the potential of these therapies to improve metabolic health and quality of life while underscoring the clinical, ethical and practical complexities that accompany their broader adoption. Individuals considering similar treatments benefit from rigorous medical assessment, clear goals, careful monitoring and an understanding of how medication can interact with—and support—lifestyle changes.